Design of postmetallocene catalytic systems of arylimine type for olefin polymerization: XVII. Synthesis of methoxy-substituted (p-aryl)salicylaldimines containing ω-alkenyloxy group, and their complexes with titanium(IV) dichloride
作者:I. I. Oleinik、I. V. Oleinik、S. S. Ivanchev、G. A. Tolstikov
DOI:10.1134/s1070428014110050
日期:2014.11
Reaction of 5-methoxy-substituted salicylic aldehydes containing in the position 3 tert-butyl, 2-phenylpropan-2-yl, or 1-phenylethyl groups with m- and p-allyloxy-, (but-3-enyloxy)-, (pent-4-enyloxy)anilines without solvent in an open system at 130°C afforded a series of (N-aryl)salicylaldimines L that with TiCl2 (OPr-i)2 formed complexes of titanium(IV) dichloride L2TiCl2.
在3位叔丁基,2-苯基丙烷-2-基或1-苯基乙基上的5-甲氧基取代的水杨醛与m-和p-烯丙氧基-(but-3-enyloxy)-,(在没有溶剂的情况下,在130°C的开放系统中进行戊-4-烯氧基)苯胺制得的一系列(N-芳基)水杨醛亚胺L与TiCl 2(OPr- i)2形成二氯化钛(IV)L 2 TiCl 2的配合物。
Discovery of the Macrocycle 11-(2-Pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (SB1518), a Potent Janus Kinase 2/Fms-Like Tyrosine Kinase-3 (JAK2/FLT3) Inhibitor for the Treatment of Myelofibrosis and Lymphoma
作者:Anthony D. William、Angeline C.-H. Lee、Stéphanie Blanchard、Anders Poulsen、Ee Ling Teo、Harish Nagaraj、Evelyn Tan、Dizhong Chen、Meredith Williams、Eric T. Sun、Kee Chuan Goh、Wai Chung Ong、Siok Kun Goh、Stefan Hart、Ramesh Jayaraman、Mohammed Khalid Pasha、Kantharaj Ethirajulu、Jeanette M. Wood、Brian W. Dymock
DOI:10.1021/jm200326p
日期:2011.7.14
Discovery of the activating mutation V617F in Janus Kinase 2 (JAK2(V617F)), a tyrosine kinase critically involved in receptor signaling, recently ignited interest in JAK2 inhibitor therapy as a treatment for myelofibrosis (ME). Herein, we describe the design and synthesis of a series of small molecule 4-aryl-2-aminopyrimidine macrocycles and their biological evaluation against the JAK family of kinase enzymes and FLT3. The most promising leads were assessed for their in vitro ADME properties culminating in the discovery of 21c, a potent JAK2 (IC50 = 23 and 19 nM for JAK2(WT) and JAK2(V617F), respectively) and FLT3 (IC50 = 22 nM) inhibitor with selectivity against JAK1 and JAK3 (IC50 = 1280 and 520 nM, respectively). Further profiling of 21c in preclinical species and mouse xenograft and allograft models is described. Compound 21c (SB1518) was selected as a development candidate and progressed into clinical trials where it is currently in phase 2 for ME and lymphoma.